

PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME

Zepatier (



CareSource considers Zepatier (grazoprevir/elbasvir) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

LLLLwBDC /TT1 1 Tf -BC /5 2Tf 9.967ILwB CrC Cr 1 Tf 9.900Q EMC Q BLwf -0ce 5ope /Footer /Typ81eLwf -0cepe /Footer /T

Appendix. Treatment Duration

Genotype and Population	Treatment	Duration
Genotype 1a: Treatment-naïve or PegIFN/RBV experienced ¹ without baseline NS5A polymorphisms ²	Zepatier	12 weeks
Genotype 1a: Treatment-naïve or PegIFN/RBV experienced ¹ with baseline NS5A polymorphisms ²	Zepatier + ribavirin	16 weeks
Genotype 1b: Treatment-naïve or PegIFN/RBV experienced ¹	Zepatier	12 weeks
Genotype 1a or 1b: PegIFN/RBV/PI-experienced ³	Zepatier + ribavirin	12 weeks
Genotype 4: Treatment-naïve	Zepatier	12 weeks
Genotype 4: PegIFN/RBV-experienced ¹	Zepatier + ribavirin	16 weeks

¹Peginterferon alfa + ribavirin.

²Polymorphisms at amino acid positions 28, 30, 31, or 93.

³Peginterferon alfa + ribavirin + HCV NS3/4A protease inhibitor.